WS #11795

15:12→15:42 UTC

From 499 msgs · 6 key-dev

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses primary goal, favoring existing and next-gen therapies.

Ionis/AstraZeneca ATTR-CM Trial Miss

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses primary goal, favoring existing and next-gen therapies.